Jonathan Lee, Chief Hematology, Oncology Fellow at NYP-Weill Cornell Thoracic + GI Oncology, shared a post on LinkedIn:
“Excited to share our recent publication looking at PD-L1 as a predictive biomarker to Osimertinib therapy in 1L EGFR-mt NSCLC (N=101).
PD-L1 ≥1% had lower RR, PFS, and OS.
What does PD-L1 expression represent beyond immune evasion, especially in the context of EGFR-mt?
Stay tuned for an ongoing international collaboration to explore these questions!”
Title: Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression
Authors: Jonathan W. Lee, Xiao Jin, Stephanie Bogdan, Ayman Abou-Alfa, Josephine Chang, Michael Rafizadeh, Eric C. Kang, Christine Garcia, Xi Kathy Zhou, Ashish Saxena
Read The Full Article
More posts about PD-L1 on OncoDaily.